ArticleNorth Carolina medical journal2024
Sarcoidosis Mortality in North Carolina: Role of Region, Race, and Other Sociodemographic Variables.
Article in North Carolina medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.The Lancet. Respiratory medicine · 2026Review
- Comparative Analysis of LLMs in Dry Eye Syndrome Healthcare Information.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is regional variability in sarcoidosis mortality across the United States. North Carolina ranks highly in sarcoidosis-related mortality, especially among African Americans (AA). We sought to determine any regional variability of sarcoidosis-related mortality and the relationship to sociodemographic determinants of health in North Carolina. Methods: Counties in North Carolina were categorized into three distinct geographic regions: Western, Piedmont, and Eastern. Sarcoidosis deaths were stratified by region, race, and gender. We conducted a mapping and cluster analysis utilizing ArcGIS; Global and Local Moran's I was used to determine the prevalence, spatial autocorrelation, and clustering of mortality vis-a-vis various sociodemographic variables, occupational/environmental exposures, and levels of atmospheric particulate matter less than 2.5 microns in size (PM2.5). Multivariate linear regression with exposure limited to the county level was used to determine the relationship between sarcoidosis mortality and the variables of interest. Results: Eastern North Carolina (ENC) had the highest age-adjusted sarcoidosis mortality rate (1.16/100,000 versus 0.49/100,000 in Piedmont and 0.32/100,000 in the Western region) with statistically significant high-high mortality clusters (P < .001 for Global Moran's I). Several sociodemographic and occupational factors (proportion of AA, obese adults, and individuals working in nature) were more prevalent in ENC. Region and proportion of AA were the significant mortality predictors in our multivariate analysis. Limitations: This was a cross-sectional study with exposure limited to the county level. Associations do not imply causality and risks cannot be extrapolated to the individual level. Conclusion: There is regional variability of sarcoidosis mortality in North Carolina. Eastern North Carolina had the highest mortality with high-high mortality clusters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.